Biosign grants 3,115,000 stock options at $0.92 per share

Biosign Technologies Inc. (TSXV: BIO, "Biosign") announced today the grant of an aggregate of 3,115,000 stock options pursuant to the Company's stock option plan. An aggregate of 1,115,000 of such options were granted effective June 16, 2011 to four directors of the Company.  These options expire in 5 years, have an exercise price of $0.92 per share and, in certain cases, are subject to vesting. Two million of such options were granted effective June 22, 2011 to Dr. Scott Jenkins in connection with his appointment as Chief Executive Officer of the Company.  These options expire in 5 years, are subject to vesting, have an exercise price of $0.92 per share and are subject to receipt of all necessary regulatory and shareholder approvals.

Source: BIOSIGN TECHNOLOGIES INC.